Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
Authors
Keywords
Pancreatic carcinoma, EGFR inhibitor, Nimotuzumab, Gemcitabine, Monoclonal antibody
Journal
TUMOR BIOLOGY
Volume 35, Issue 3, Pages 2313-2318
Publisher
Springer Nature
Online
2013-10-18
DOI
10.1007/s13277-013-1306-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)
- (2013) H. Fensterer et al. ANNALS OF ONCOLOGY
- Cetuximab: still an option in the treatment of pancreatic cancer?
- (2013) Luca Faloppi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Targeting EGFR in Pancreatic Cancer Treatment
- (2012) T. Troiani et al. CURRENT DRUG TARGETS
- Current Status and Perspectives of Targeted Therapy in Well-Differentiated Neuroendocrine Tumors
- (2012) Boris G. Naraev et al. ONCOLOGY
- Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer
- (2012) Karim M. Eltawil et al. HPB
- Management strategies in pancreatic cancer
- (2011) C. J. Campen et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
- (2011) D. Strumberg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
- (2011) Jing Hu et al. Journal of Hematology & Oncology
- Genomics and pharmacogenomics of pancreatic adenocarcinoma
- (2011) M A Lowery et al. PHARMACOGENOMICS JOURNAL
- Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
- (2010) Dirk Strumberg et al. INVESTIGATIONAL NEW DRUGS
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
- (2009) A. Talavera et al. CANCER RESEARCH
- Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
- (2009) William Kells Boland et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab
- (2007) Fernando Rivera et al. ACTA ONCOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now